Literature DB >> 9423162

Solid-state characterization of paclitaxel.

R T Liggins1, W L Hunter, H M Burt.   

Abstract

The purpose of this work was to characterize the solid-state properties of anhydrous paclitaxel and paclitaxel dihydrate. Paclitaxel I (anhydrous) was suspended in water for 24 h to convert it to paclitaxel.2H2O. Both forms were analyzed by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). X-ray powder diffraction (XRPD) patterns were obtained at 25, 100, and 195 degrees C. Dissolution profiles of both forms were obtained in water at 37 degrees C over h. DSC of paclitaxel.2H2O showed two endothermic peaks below 100 degrees C, corresponding to dehydration. The resulting solid phase was termed "dehydrated paclitaxel.2H2O". At 168 degrees C, a solid-solid transition was observed in which dehydrated paclitaxel.2H2O was converted to a semicrystalline material called "paclitaxel I/am". The solid-solid transition was followed by melting at 220 degrees C. TGA of paclitaxel.2H2O showed a corresponding biphasic weight loss below 100 degrees C, which was equivalent to the weight of 2 mol of water. DSC of paclitaxel I showed no transitions before melting at 220 degrees C, and no weight loss was observed by TGA. Quenching of paclitaxel I from the melt produced amorphous paclitaxel with a glass transition at 152 degrees C. XRPD confirmed that paclitaxel I, paclitaxel.2H2O, and dehydrated paclitaxel.2H2O had different crystal structures. The X-ray patterns of paclitaxel I and paclitaxel I/am were similar, however the two forms of paclitaxel did not behave identically when analyzed by DSC. The bulk dissolution studies with paclitaxel I showed a rapid increase in concentration to 3 micrograms/mL in 4 h, which decreased to 1 microgram/mL after 12 h, corresponding to the solubility of paclitaxel.2H2O. The solubility of paclitaxel.2H2O was 1 microgram/mL. The data demonstrate the existence of a dihydrate form of paclitaxel that is the stable form in equilibrium with water at 37 degrees C but which dehydrates at temperatures > 45 degrees C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9423162     DOI: 10.1021/js9605226

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  35 in total

1.  A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Authors:  Ho-Chul Shin; Adam W G Alani; Hyunah Cho; Younsoo Bae; Jill M Kolesar; Glen S Kwon
Journal:  Mol Pharm       Date:  2011-06-23       Impact factor: 4.939

2.  Development of paclitaxel-TyroSpheres for topical skin treatment.

Authors:  Brian E Kilfoyle; Larisa Sheihet; Zheng Zhang; Marissa Laohoo; Joachim Kohn; Bozena B Michniak-Kohn
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

3.  Investigation of formulation variables and excipient interaction on the production of niosomes.

Authors:  Zerrin Sezgin-Bayindir; Nilufer Yuksel
Journal:  AAPS PharmSciTech       Date:  2012-05-30       Impact factor: 3.246

4.  Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.

Authors:  Zhijian He; Anita Schulz; Xiaomeng Wan; Joshua Seitz; Herdis Bludau; Daria Y Alakhova; David B Darr; Charles M Perou; Rainer Jordan; Iwao Ojima; Alexander V Kabanov; Robert Luxenhofer
Journal:  J Control Release       Date:  2015-02-26       Impact factor: 9.776

5.  Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.

Authors:  Fei Ren; Ruda Chen; Ying Wang; Yabin Sun; Yaodong Jiang; Guofeng Li
Journal:  Pharm Res       Date:  2010-12-24       Impact factor: 4.200

6.  Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods.

Authors:  Loan Huynh; Justin Grant; Jean-Christophe Leroux; Pascal Delmas; Christine Allen
Journal:  Pharm Res       Date:  2007-08-18       Impact factor: 4.200

7.  Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.

Authors:  Wenbo Zhan; Davis Yohanes Arifin; Timothy Ky Lee; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2017-02-02       Impact factor: 4.200

8.  Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment.

Authors:  Duy Toan Pham; Nuttawut Saelim; Waree Tiyaboonchai
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

9.  Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850).

Authors:  Julie A Straub; Donald E Chickering; Jonathan C Lovely; Huimin Zhang; Bhavdeep Shah; William R Waud; Howard Bernstein
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

10.  Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.

Authors:  Samantha A Meenach; Kimberly W Anderson; J Zach Hilt; Ronald C McGarry; Heidi M Mansour
Journal:  Eur J Pharm Sci       Date:  2013-05-23       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.